Search
for
Sort by
Research 391–420 of 1000+
- Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study
- Ethanol Enhances Neurosteroidogenesis in Hippocampal Pyramidal Neurons by Paradoxical NMDA Receptor Activation
- Hair Loss in Women
- Large Scale Gene Expression Profiles of Regenerating Inner Ear Sensory Epithelia
- The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression
- Steroid 5α-Reductase as a Novel Therapeutic Target for Schizophrenia and Other Neuropsychiatric Disorders
- The Effect of 5α-Reductase Inhibition With Dutasteride and Finasteride on Bone Mineral Density, Serum Lipoproteins, Hemoglobin, Prostate Specific Antigen and Sexual Function in Healthy Young Men
- Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation
- Frontal fibrosing alopecia: treatment with oral dutasteride and topical pimecrolimus
- Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis
- The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit–risk assessment of finasteride and dutasteride
- Treatment of postmenopausal frontal fibrosing alopecia with oral dutasteride
- 5alpha-reductase: history and clinical importance.
- Discovery and Clinical Development of Dutasteride, a Potent Dual 5α- Reductase Inhibitor
- Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials
- 5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes
- Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia
- An update of anti-viral treatment of COVID-19
- Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases
- Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride
- Anti‐androgens may protect against severe COVID‐19 outcomes: results from a prospective cohort study of 77 hospitalized men
- Actions of 5α-reductase inhibitors on the epididymis
- Preparation and characterization of dutasteride-loaded nanostructured lipid carriers coated with stearic acid-chitosan oligomer for topical delivery
- 5 Alpha-reductase inhibitors: whatʼs new?
- Clinical application of 5α-reductase inhibitors
- Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride
- Dutasteride
- 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review
- Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical)
- SLE and Serum Complement: Causative, Concomitant or Coincidental?